How to Switch from Clonazepam to Lorazepam (Ativan)
Use a gradual cross-taper over 2-4 weeks, converting clonazepam to an equivalent lorazepam dose using a 1:2 ratio (1 mg clonazepam = 2 mg lorazepam), then slowly transitioning between medications while monitoring for withdrawal symptoms.
Dose Conversion
For your patient taking clonazepam 0.75 mg AM, 0.5 mg midday, and 0.5 mg PM (total 1.75 mg/day):
- Equivalent lorazepam dose: 3.5 mg/day total
- Morning: 1.5 mg
- Midday: 1 mg
- Evening: 1 mg
Recommended Cross-Taper Protocol
Week 1-2: Initial Substitution
- Morning: Replace clonazepam 0.75 mg with lorazepam 1.5 mg
- Midday: Continue clonazepam 0.5 mg
- Evening: Continue clonazepam 0.5 mg
Week 3: Continue Transition
- Morning: Lorazepam 1.5 mg
- Midday: Replace clonazepam 0.5 mg with lorazepam 1 mg
- Evening: Continue clonazepam 0.5 mg
Week 4: Complete Switch
- Morning: Lorazepam 1.5 mg
- Midday: Lorazepam 1 mg
- Evening: Replace clonazepam 0.5 mg with lorazepam 1 mg
Critical Pharmacological Considerations
Clonazepam has a significantly longer half-life (30-40 hours) compared to lorazepam (10-20 hours) 1. This fundamental difference means:
- Clonazepam provides more stable blood levels throughout the day
- Lorazepam requires more frequent dosing to prevent breakthrough withdrawal
- The switch may initially cause interdose withdrawal symptoms due to lorazepam's shorter duration
The conversion ratio of 1:2 (clonazepam:lorazepam) is based on benzodiazepine equivalency tables used in clinical practice 2. However, individual response varies, and some patients may require dose adjustments.
Monitoring for Withdrawal Symptoms
Watch closely for these withdrawal signs, which can emerge during the cross-taper 3:
Common symptoms:
- Anxiety and restlessness
- Insomnia or sleep disturbance
- Tremor or muscle twitching
- Sweating
- Irritability
- Difficulty concentrating
Severe symptoms requiring immediate intervention:
- Seizures
- Confusion or delirium
- Severe agitation
- Hallucinations
- Marked tachycardia or hypertension
Important Clinical Pitfalls
Do not attempt an abrupt switch. Both medications carry FDA warnings that abrupt discontinuation can precipitate life-threatening withdrawal reactions, including seizures 3, 4. The long half-life of clonazepam means withdrawal symptoms may be delayed by several days after stopping.
Avoid linear dose reductions. Recent evidence suggests that proportionate (hyperbolic) tapering produces more tolerable transitions than linear reductions, as benzodiazepine receptor occupancy follows a hyperbolic curve 5. If the patient experiences significant withdrawal symptoms, slow the taper rate.
Consider the reason for switching. If switching due to clonazepam side effects (morning sedation, cognitive impairment, falls risk), lorazepam's shorter half-life may help 1. However, if the goal is eventual discontinuation, staying on clonazepam and tapering directly may be preferable since its longer half-life makes withdrawal more gradual 6, 5.
Alternative Approach: Slower Cross-Taper
For patients with history of difficult benzodiazepine withdrawal or high anxiety sensitivity, consider a more conservative 6-8 week cross-taper:
- Replace one dose every 2 weeks instead of weekly
- Make smaller incremental changes (e.g., replace 50% of a dose, then 100% two weeks later)
- Add supportive measures like cognitive-behavioral strategies 7
Special Considerations
Elderly patients or those with hepatic impairment: Start with lower lorazepam doses (reduce by 25-50%) as both medications are metabolized hepatically, but lorazepam undergoes simpler glucuronidation 4.
Patients on opioids or other CNS depressants: Exercise extreme caution during the cross-taper due to additive respiratory depression risk 3, 4. Consider closer monitoring or inpatient transition if high-dose opioids are involved.
Duration of prior clonazepam use matters: Patients on clonazepam for years may have developed significant physical dependence and require slower transitions 3, 6.